Join to View Full Profile
8001 Frost StSan Diego, CA 92123
Phone+1 858-966-5819
Dr. Gold is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Diego) Medical CenterFellowship, Clinical Neurophysiology, 2013 - 2014- University of California (San Diego) Medical CenterFellowship, Child Neurology, 2010 - 2013
- University of California (San Diego) Medical CenterResidency, Pediatrics, 2008 - 2010
University of California San Diego School of MedicineClass of 2008
Certifications & Licensure
CA State Medical License 2010 - 2027
American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology- American Board of Psychiatry and Neurology Clinical Neurophysiology
- American Board of Psychiatry and Neurology Epilepsy
Publications & Presentations
PubMed
- 1 citationsRestricted diffusion of the callosal splenium is highly specific for seizures in neonates.Linda Nguyen, Dillon Y Chen, Daniel N Vinocur, Jeffrey J Gold
BMC Neurology. 2022-12-06 - Safety of Early Discontinuation of Antiseizure Medication After Acute Symptomatic Neonatal Seizures.John R. Crawford, Jeffrey I. Gold, Richard H. Haas
JAMA Neurology. 2021-11-15 - 9 citationsDoes the first hour of continuous electroencephalography predict neonatal seizuresEmma Macdonald-Laurs, Cynthia Sharpe, Mark Nespeca, Neggy Rismanchi, Jeffrey J. Gold
Archives of Disease in Childhood. Fetal and Neonatal Edition. 2021-03-01
Journal Articles
- Rapid Diagnosis of KCNQ2 Associated Early Infantile Epileptic Encephalopathy Improved OutcomeJennifer R Friedman, Jeffrey J Gold, Pediatric Neurology
Authored Content
- Rapid Diagnosis of KCNQ2 Associated Early Infantile Epileptic Encephalopathy Improved OutcomeJuly 2018
Grant Support
- NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)UNIVERSITY OF MINNESOTA2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
